{"id":"placebo-endocrine-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Vaginal dryness or sexual dysfunction"},{"rate":null,"effect":"Bone loss / osteoporosis"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Arthralgia"}]},"_chembl":{"chemblId":"CHEMBL4298181","moleculeType":"Gene"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Endocrine therapy (such as aromatase inhibitors, tamoxifen, or androgen deprivation therapy) works by suppressing or blocking sex hormone receptors that drive growth of hormone-sensitive tumors. This Phase 3 trial appears to compare placebo plus endocrine therapy, likely as a control arm or to evaluate the endocrine therapy component in hormone-responsive cancers. The exact endocrine agent is not specified in the provided information.","oneSentence":"A combination therapy using placebo with endocrine therapy to treat hormone-responsive cancers by blocking estrogen or androgen signaling.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:26:51.143Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone-responsive breast cancer (presumed, based on endocrine therapy use)"},{"name":"Hormone-responsive prostate cancer (presumed, based on endocrine therapy use)"}]},"trialDetails":[{"nctId":"NCT04484818","phase":"PHASE3","title":"Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-03-01","conditions":"Prostate Carcinoma","enrollment":27},{"nctId":"NCT07174336","phase":"PHASE3","title":"A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-12-22","conditions":"Breast Neoplasms, Neoplasm Metastasis","enrollment":920},{"nctId":"NCT03767244","phase":"PHASE3","title":"A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-06-11","conditions":"Prostatic Neoplasms","enrollment":2517},{"nctId":"NCT02531516","phase":"PHASE3","title":"An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2015-11-19","conditions":"Prostatic Neoplasms","enrollment":1503},{"nctId":"NCT07310901","phase":"PHASE1","title":"A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity","status":"RECRUITING","sponsor":"Corbus Pharmaceuticals Inc.","startDate":"2025-12-04","conditions":"Obese But Otherwise Healthy Participants","enrollment":252},{"nctId":"NCT06382948","phase":"PHASE3","title":"Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.","status":"RECRUITING","sponsor":"MedSIR","startDate":"2024-12-05","conditions":"Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":240},{"nctId":"NCT02712723","phase":"PHASE2","title":"Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qamar Khan","startDate":"2016-02","conditions":"Breast Cancer","enrollment":121},{"nctId":"NCT05726292","phase":"PHASE2","title":"A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-01-06","conditions":"Prostate Cancer, Prostate Adenocarcinoma","enrollment":90},{"nctId":"NCT05894239","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-09-08","conditions":"Metastatic Breast Cancer","enrollment":230},{"nctId":"NCT06617455","phase":"PHASE2","title":"Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial","status":"TERMINATED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2024-10-31","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8","enrollment":9},{"nctId":"NCT01602380","phase":"PHASE3","title":"A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-10-17","conditions":"Hormone Receptor Positive Breast Cancer","enrollment":462},{"nctId":"NCT06440967","phase":"PHASE3","title":"A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2024-07-31","conditions":"Hot Flashes","enrollment":540},{"nctId":"NCT07400653","phase":"PHASE3","title":"A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-02-12","conditions":"Obesity, Overweight and/or Obesity, Overweight","enrollment":999},{"nctId":"NCT01674140","phase":"PHASE3","title":"S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2013-09-12","conditions":"Breast Cancer","enrollment":1939},{"nctId":"NCT06917313","phase":"PHASE2","title":"FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-12-05","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3)","enrollment":92},{"nctId":"NCT07393321","phase":"PHASE3","title":"A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Nanjing Chia-tai Tianqing Pharmaceutical","startDate":"2026-02-10","conditions":"HR Positive/HER2 Negative Advanced or Metastatic Breast Cancer","enrollment":210},{"nctId":"NCT05587296","phase":"PHASE3","title":"A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2022-10-14","conditions":"Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes","enrollment":474},{"nctId":"NCT03928288","phase":"PHASE2","title":"Cabergoline for the Treatment of Chronic Pain Due to Endometriosis","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2019-12-02","conditions":"Endometriosis","enrollment":129},{"nctId":"NCT05169567","phase":"PHASE3","title":"Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-03-11","conditions":"Breast Neoplasm, Neoplasm Metastasis","enrollment":368},{"nctId":"NCT04964934","phase":"PHASE3","title":"Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-30","conditions":"ER-Positive HER2-Negative Breast Cancer","enrollment":315},{"nctId":"NCT05838716","phase":"PHASE3","title":"Vitamin D for Prostate Endocrine Therapy","status":"RECRUITING","sponsor":"University of Rochester","startDate":"2023-12-14","conditions":"Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8","enrollment":240},{"nctId":"NCT05860465","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","startDate":"2023-09-08","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":254},{"nctId":"NCT07340658","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Palbociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Rovi Pharmaceuticals Laboratories","startDate":"2026-05","conditions":"Advanced, Metastatic Breast Cancer","enrollment":300},{"nctId":"NCT06807580","phase":"PHASE2","title":"Progesterone in Gender Affirming Hormone Therapy Study","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-05-12","conditions":"Transgender Women","enrollment":40},{"nctId":"NCT07003763","phase":"NA","title":"Electroacupuncture on Treating Cancer-related Depression","status":"RECRUITING","sponsor":"Shanghai Municipal Hospital of Traditional Chinese Medicine","startDate":"2025-07-01","conditions":"Depression, Cancer","enrollment":86},{"nctId":"NCT02115282","phase":"PHASE3","title":"Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-03-29","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma","enrollment":608},{"nctId":"NCT06787118","phase":"PHASE3","title":"Study Assessing the Efficacy and Safety of cANnabidiol Oral Solution for Joint Pain of Adjuvant enDOcrine theRApy in Patients With Early Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-12","conditions":"Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III","enrollment":130},{"nctId":"NCT04419779","phase":"NA","title":"Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes","status":"SUSPENDED","sponsor":"Fractyl Health Inc.","startDate":"2021-03-08","conditions":"Type 2 Diabetes","enrollment":320},{"nctId":"NCT03671330","phase":"PHASE2","title":"Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-08-29","conditions":"Breast Cancer","enrollment":327},{"nctId":"NCT07050563","phase":"NA","title":"Clinical Evaluation of the Tiaoshen Anti-Cancer Regimen in Treating Psycho-Neurological Symptom Cluster in Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Municipal Hospital of Traditional Chinese Medicine","startDate":"2025-10-06","conditions":"Cancer, Cancer Symptom Clusters","enrollment":316},{"nctId":"NCT07171723","phase":"PHASE1, PHASE2","title":"Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment","status":"RECRUITING","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2025-09-01","conditions":"Obesity &Amp; Overweight","enrollment":24},{"nctId":"NCT03945812","phase":"PHASE4","title":"Platelet-Rich Plasma vs. Granulocyte Colony-Stimulating Factor vs. Placebo and Outcomes in Frozen Embryo Transfer","status":"COMPLETED","sponsor":"Wael Elbanna Clinic","startDate":"2019-06-01","conditions":"Infertility, Frozen Embryo Transfer (FET)","enrollment":665},{"nctId":"NCT04752332","phase":"PHASE3","title":"A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2021-05-10","conditions":"Breast Neoplasms","enrollment":111},{"nctId":"NCT06856174","phase":"PHASE4","title":"Menopausal HT for Women Living With HIV (HoT)","status":"NOT_YET_RECRUITING","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2026-01-19","conditions":"HIV Infection, Menopause","enrollment":105},{"nctId":"NCT03725059","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-27","conditions":"Breast Cancer","enrollment":1240},{"nctId":"NCT01419730","phase":"PHASE2","title":"Vitamin D and Physical Activity on Bone Health","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Rochester","startDate":"2011-08","conditions":"Bone Metabolism Biomarkers, Bone Mineral Density, Physical Fitness","enrollment":191},{"nctId":"NCT06998108","phase":"PHASE3","title":"Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy","status":"RECRUITING","sponsor":"BeBetter Med Inc","startDate":"2022-06-09","conditions":"HR+/HER2- Locally Advanced, Metastatic Breast Cancer","enrollment":330},{"nctId":"NCT01805271","phase":"PHASE3","title":"Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2013-03","conditions":"Primary Non-metastatic Breast Cancer, Who Remain Disease-free","enrollment":1278},{"nctId":"NCT00687739","phase":"PHASE3","title":"Prevention of Obesity in Women Via Estradiol Regulation","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2008-05","conditions":"Obesity","enrollment":79},{"nctId":"NCT04600336","phase":"PHASE2","title":"Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2021-10-28","conditions":"Prostate Carcinoma","enrollment":88},{"nctId":"NCT04283656","phase":"PHASE1","title":"Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2022-01-04","conditions":"Transgender Health, Gender Dysphoria, Transgender Women","enrollment":8},{"nctId":"NCT06880484","phase":"NA","title":"Far-Infrared Socks for Neuropathic Pain and Nerve Function in Diabetic Patients","status":"ENROLLING_BY_INVITATION","sponsor":"TC Erciyes University","startDate":"2025-02-02","conditions":"Diabetic Peripheral Neuropathy (DPN)","enrollment":50},{"nctId":"NCT06774885","phase":"PHASE3","title":"ROLE OF FOLIC ACID IN THE MANAGEMENT OF ADJUVANT ENDOCRINE THERAPY-INDUCED HOT FLASHES IN BREAST CANCER PATIENTS","status":"NOT_YET_RECRUITING","sponsor":"Future University in Egypt","startDate":"2025-02-09","conditions":"THERAPY-INDUCED HOT FLASHES IN BREAST CANCER PATIENTS","enrollment":120},{"nctId":"NCT04109066","phase":"PHASE3","title":"Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-11-18","conditions":"Breast Cancer","enrollment":521},{"nctId":"NCT05063136","phase":"PHASE3","title":"Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2021-09-28","conditions":"Breast Cancer","enrollment":1979},{"nctId":"NCT05054751","phase":"PHASE3","title":"GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Genor Biopharma Co., Ltd.","startDate":"2021-09-10","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":275},{"nctId":"NCT00626106","phase":"PHASE2","title":"QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"NantCell, Inc.","startDate":"2008-03-27","conditions":"Breast Cancer, Breast Tumors, Metastatic Cancer","enrollment":156},{"nctId":"NCT06379659","phase":"PHASE1, PHASE2","title":"Effectiveness of Intrauterine Growth Hormone Administration as an add-on Therapy to Conventional Hormone Therapy Compared to Placebo in Patients With Thin Endometrium Undergoing Frozen Thawed Embryo Transfer","status":"COMPLETED","sponsor":"Isfahan University of Medical Sciences","startDate":"2024-05-01","conditions":"Thin Endometrium, Infertility Female, Infertility","enrollment":54},{"nctId":"NCT04842617","phase":"PHASE3","title":"Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-04-30","conditions":"Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer","enrollment":5274},{"nctId":"NCT02599714","phase":"PHASE1","title":"Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-12-07","conditions":"Advanced and Metastatic Breast Cancer","enrollment":54},{"nctId":"NCT05586724","phase":"PHASE3","title":"Micronized Progesterone Versus Norethisterone Acetate in Combination With Estrogen as Menopausal Hormone Therapy","status":"RECRUITING","sponsor":"Angelica Lindén Hirschberg","startDate":"2022-03-15","conditions":"Menopausal Symptoms","enrollment":520},{"nctId":"NCT01942135","phase":"PHASE3","title":"Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-09-26","conditions":"Metastatic Breast Cancer","enrollment":521},{"nctId":"NCT00382070","phase":"PHASE3","title":"Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"NSABP Foundation Inc","startDate":"2006-08","conditions":"Breast Cancer","enrollment":3966},{"nctId":"NCT06091761","phase":"NA","title":"Thread Embedding Acupuncture Combined With Auricular Acupuncture for Overweight and Obesity","status":"COMPLETED","sponsor":"University of Medicine and Pharmacy at Ho Chi Minh City","startDate":"2023-10-30","conditions":"Overweight or Obesity","enrollment":66},{"nctId":"NCT03653091","phase":"NA","title":"Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"Fractyl Health Inc.","startDate":"2018-09-28","conditions":"Type 2 Diabetes","enrollment":9},{"nctId":"NCT05276401","phase":"PHASE2","title":"Nu-3 Topical Gel for Treatment of Diabetic Foot Ulcer","status":"TERMINATED","sponsor":"Lakewood-Amedex Inc","startDate":"2022-03-11","conditions":"Chronic Diabetic Foot Ulcers","enrollment":3},{"nctId":"NCT05733455","phase":"PHASE1","title":"Effect of Alpelisib in Healthy Volunteers","status":"COMPLETED","sponsor":"Columbia University","startDate":"2023-05-09","conditions":"Insulin Resistance, Hyperinsulinemia, Dyslipidemias","enrollment":23},{"nctId":"NCT04071626","phase":"PHASE4","title":"Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure","status":"TERMINATED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2020-03-01","conditions":"Heart Failure, Diastolic, Diabetes Mellitus, Type 2","enrollment":9},{"nctId":"NCT01864746","phase":"PHASE3","title":"A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2013-10-30","conditions":"Breast Cancer, Hormonreceptor Positive, Her2-normal","enrollment":1250},{"nctId":"NCT02422615","phase":"PHASE3","title":"Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-06-09","conditions":"Advanced Breast Cancer","enrollment":726},{"nctId":"NCT06061666","phase":"NA","title":"Treatment of Insomnia in Patients With Breast Cancer","status":"UNKNOWN","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2023-06-01","conditions":"Breast Cancer, Insomnia","enrollment":80},{"nctId":"NCT05982470","phase":"PHASE2","title":"Effect of Menopause Hormone Therapy In Postmenopausal Women With CSVD And MCI","status":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","startDate":"2023-08-18","conditions":"Cerebral Small Vessel Diseases, Postmenopausal Symptoms, Mild Cognitive Impairment","enrollment":328},{"nctId":"NCT05433480","phase":"PHASE3","title":"A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2022-05-25","conditions":"Breast Cancer","enrollment":274},{"nctId":"NCT03718494","phase":"","title":"Continuation of The Kronos Early Estrogen Prevention Study (KEEPS)","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-05-22","conditions":"Alzheimer Dementia","enrollment":299},{"nctId":"NCT04354896","phase":"PHASE4","title":"The Effect of Thyroid Hormone Therapy on Muscle Mass and Function in Older Adults With Subclinical Hypothyroidism","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2014-05","conditions":"Subclinical Hypothyroidism, Sarcopenia","enrollment":322},{"nctId":"NCT05780567","phase":"PHASE3","title":"Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-03-30","conditions":"Breast Cancer","enrollment":1946},{"nctId":"NCT03969121","phase":"PHASE3","title":"Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer","status":"COMPLETED","sponsor":"Kyoto Breast Cancer Research Network","startDate":"2019-07-16","conditions":"Breast Cancer Female, Hormone Receptor Positive Malignant Neoplasm of Breast","enrollment":141},{"nctId":"NCT05649605","phase":"NA","title":"Early Mental Response - The EMRE Study","status":"RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2023-03-07","conditions":"Gender Dysphoria, Gender Identity, Gender Issues","enrollment":70},{"nctId":"NCT01478477","phase":"NA","title":"Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2011-10-04","conditions":"Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer","enrollment":44},{"nctId":"NCT03038594","phase":"PHASE2, PHASE3","title":"Growth Hormone Therapy for Muscle Regeneration in Severely Burned Patients","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2015-11-01","conditions":"Burns, Growth Hormone Treatment","enrollment":13},{"nctId":"NCT00114517","phase":"PHASE2","title":"ELITE: Early Versus Late Intervention Trial With Estradiol","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2004-07","conditions":"Atherosclerosis","enrollment":643},{"nctId":"NCT04887701","phase":"NA","title":"Non-hormonal Medical Device for Treatment of Vulvovaginal Atrophy (VVA) in Post-Menopausal Women","status":"COMPLETED","sponsor":"Madorra","startDate":"2021-07-09","conditions":"Vulvovaginal Atrophy","enrollment":25},{"nctId":"NCT05660356","phase":"EARLY_PHASE1","title":"Growth Hormone Deficiency in Mild Traumatic Brain Injury","status":"UNKNOWN","sponsor":"University of Calgary","startDate":"2023-02","conditions":"Growth Hormone Treatment, Growth Hormone Deficiency, Concussion, Mild","enrollment":20},{"nctId":"NCT01598298","phase":"PHASE3","title":"S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2013-05-15","conditions":"Breast Cancer, Musculoskeletal Complications, Pain","enrollment":299},{"nctId":"NCT04922424","phase":"PHASE1","title":"Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men","status":"WITHDRAWN","sponsor":"Yale University","startDate":"2022-09-30","conditions":"Hypertension, Hyperlipidemias","enrollment":""},{"nctId":"NCT00842348","phase":"PHASE3","title":"Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour","status":"COMPLETED","sponsor":"Ipsen","startDate":"2009-02","conditions":"Non Functioning Entero-pancreatic Endocrine Tumour","enrollment":89},{"nctId":"NCT05105685","phase":"PHASE1, PHASE2","title":"Effectiveness of Recombinant Human Growth Hormone Therapy for Children With PMS","status":"COMPLETED","sponsor":"Affiliated Hospital of Jiangnan University","startDate":"2020-06-14","conditions":"Phelan-McDermid Syndrome, Growth Hormone Treatment","enrollment":6},{"nctId":"NCT01329757","phase":"PHASE3","title":"Efficacy and Safety of Growth Hormone Treatment in Spinal Cord Injury","status":"COMPLETED","sponsor":"Hospital Nacional de Parapléjicos de Toledo","startDate":"2011-04","conditions":"Spinal Cord Injury","enrollment":76},{"nctId":"NCT04412694","phase":"PHASE4","title":"The Effect of Preoperative Oral Dexamethasone Supplementation on the Outcome of Thyroidectomised Patients.","status":"UNKNOWN","sponsor":"Medical University of Lodz","startDate":"2020-07-01","conditions":"Hypocalcemia, Vitamin D Deficiency, Postoperative Complications","enrollment":100},{"nctId":"NCT02122198","phase":"NA","title":"Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2014-09-08","conditions":"Cognitive Impairment, Executive Dysfunction, Endothelial Dysfunction","enrollment":17},{"nctId":"NCT00134056","phase":"PHASE3","title":"S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2006-08","conditions":"Metastatic Cancer, Prostate Cancer","enrollment":1038},{"nctId":"NCT03113994","phase":"PHASE2","title":"Statin Monotherapy for Treatment of Endocrine Metabolic Disease Risk","status":"UNKNOWN","sponsor":"Dr. B. Catharine. Craven","startDate":"2018-02-26","conditions":"Spinal Cord Injuries, Osteoporosis, Metabolic Syndrome","enrollment":8},{"nctId":"NCT02936687","phase":"PHASE1","title":"Mechanisms of Cerebrovascular Control","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2017-01-31","conditions":"Metabolic Syndrome X","enrollment":59},{"nctId":"NCT03078751","phase":"PHASE2","title":"Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-06-20","conditions":"Breast Cancer","enrollment":54},{"nctId":"NCT00354432","phase":"PHASE3","title":"Soy Protein/Effexor Hormone Therapy for Prostate Cancer","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2007-02-01","conditions":"Hot Flashes, Prostate Cancer","enrollment":120},{"nctId":"NCT03931928","phase":"PHASE2","title":"Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients","status":"COMPLETED","sponsor":"Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)","startDate":"2019-09-10","conditions":"Breast Cancer, DCIS","enrollment":356},{"nctId":"NCT01201863","phase":"PHASE4","title":"Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy","status":"COMPLETED","sponsor":"Craig Hospital","startDate":"2010-09","conditions":"Endocrine Dysfunction, Trauma, Brain Injury","enrollment":46},{"nctId":"NCT00570258","phase":"PHASE2","title":"Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2006-09","conditions":"Metastatic Breast Cancer","enrollment":27},{"nctId":"NCT01605071","phase":"NA","title":"Timing Estrogen After MenoPaUSe","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2011-09","conditions":"Insulin Resistance","enrollment":53},{"nctId":"NCT04050592","phase":"PHASE4","title":"Discontinuation of Postmenopausal Hormone Therapy: Impact on the Cardiovascular System and Quality of Life","status":"UNKNOWN","sponsor":"Hanna Savolainen-Peltonen","startDate":"2020-02-19","conditions":"Menopause, Atherosclerosis, Cardiovascular Diseases","enrollment":150},{"nctId":"NCT02180984","phase":"NA","title":"The Effects of Repetitive Transcranial Magnetic Stimulation in Obese People With BED","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2015-11","conditions":"Binge Eating, Obesity","enrollment":95},{"nctId":"NCT02241421","phase":"NA","title":"The Importance of the Gut Microbiota in Body Weight Control and Insulin Sensitivity","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2012-04","conditions":"Obesity, Insulin Resistance","enrollment":57},{"nctId":"NCT02258464","phase":"PHASE2","title":"Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Bayer","startDate":"2015-03-02","conditions":"Breast Neoplasms","enrollment":99},{"nctId":"NCT02429427","phase":"PHASE3","title":"European Celecoxib Trial in Primary Breast Cancer","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2005-12","conditions":"Breast Cancer","enrollment":2639},{"nctId":"NCT04420481","phase":"PHASE3","title":"Growth Hormone in Ischemic Heart Failure","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2004-04-28","conditions":"Heart Failure, Systolic, Ischemic Heart Disease Chronic","enrollment":37},{"nctId":"NCT04400968","phase":"NA","title":"Effects of Kinesiotaping vs.Auricular Therapy in Primary Dysmenorrhoea.","status":"COMPLETED","sponsor":"University of Extremadura","startDate":"2017-10-01","conditions":"Primary Dysmenorrhoea","enrollment":160},{"nctId":"NCT00973102","phase":"PHASE2","title":"Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen-Traumatic Hemorrhagic Shock (RESCUE - Shock)","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2009-07","conditions":"Hemorrhagic Shock","enrollment":50},{"nctId":"NCT02690480","phase":"PHASE2","title":"Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Spanish Breast Cancer Research Group","startDate":"2016-02-17","conditions":"Breast Neoplasms","enrollment":189},{"nctId":"NCT04113889","phase":"PHASE2","title":"Effects of Triple Drug Cocktail Therapy on Metabolic, Endocrine Alterations and Perceived Stress in Patients With Poly Cystic Ovary Syndrome","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2019-10-15","conditions":"PCOS","enrollment":147},{"nctId":"NCT02420353","phase":"PHASE2","title":"Evaluation of rGH Therapy to Prevent Muscle Atrophy in Patients With ACL Tears","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2015-05","conditions":"Rupture of Anterior Cruciate Ligament","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2701189,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Control group"],"phase":"phase_3","status":"active","brandName":"Placebo+endocrine therapy","genericName":"Placebo+endocrine therapy","companyName":"Henan Cancer Hospital","companyId":"henan-cancer-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A combination therapy using placebo with endocrine therapy to treat hormone-responsive cancers by blocking estrogen or androgen signaling. Used for Hormone-responsive breast cancer (presumed, based on endocrine therapy use), Hormone-responsive prostate cancer (presumed, based on endocrine therapy use).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}